{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33(9)"],"submitter":["Lopez-Chavez A"],"funding":["Intramural NIH HHS"],"pubmed_abstract":["Purpose
We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently.Patients and methods
We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic characterization of oncogenic drivers. Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplif"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["1000-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4356709"],"repository":["biostudies-literature"],"pubmed_title":["Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial."],"pmcid":["PMC4356709"],"pubmed_authors":["Kelly R","Rajan A","Corless CL","Carter CA","Thomas A","Meltzer PS","Killian K","Steinberg SM","Warrick A","Raffeld M","Xi L","Lopez-Chavez A","Wang Y","Morrow B","Sandler A","Liewehr DJ","Giaccone G","Pack S","Doyle A","Beadling C","Guha U","Berman A","Szabo E","Lau CC","Abdullaev Z"],"additional_accession":[]},"is_claimable":false,"name":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.","description":"Purpose
We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently.Patients and methods
We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic characterization of oncogenic drivers. Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplif","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Mar","modification":"2026-05-03T14:28:22.939Z","creation":"2019-03-27T01:48:02Z"},"accession":"S-EPMC4356709","cross_references":{"pubmed":["25667274"],"doi":["10.1200/JCO.2014.58.2007","10.1200/jco.2014.58.2007"]}}